Zacks: Analysts Anticipate Endologix, Inc. (NASDAQ:ELGX) to Post -$0.64 EPS

Wall Street brokerages predict that Endologix, Inc. (NASDAQ:ELGX) will report ($0.64) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Endologix’s earnings, with the lowest EPS estimate coming in at ($0.71) and the highest estimate coming in at ($0.57). Endologix reported earnings per share of ($1.50) in the same quarter last year, which would suggest a positive year over year growth rate of 57.3%. The business is scheduled to report its next quarterly earnings results on Thursday, November 7th.

On average, analysts expect that Endologix will report full year earnings of ($2.73) per share for the current year, with EPS estimates ranging from ($3.02) to ($2.36). For the next year, analysts forecast that the firm will post earnings of ($2.53) per share, with EPS estimates ranging from ($4.47) to ($1.71). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Endologix.

Endologix (NASDAQ:ELGX) last issued its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.43. Endologix had a negative net margin of 60.32% and a negative return on equity of 120.57%. The business had revenue of $36.24 million during the quarter, compared to analysts’ expectations of $36.09 million.

Several analysts have weighed in on ELGX shares. Royal Bank of Canada set a $7.00 price objective on shares of Endologix and gave the stock a “hold” rating in a research note on Friday, August 9th. ValuEngine upgraded shares of Endologix from a “hold” rating to a “buy” rating in a research note on Thursday, October 10th. Finally, Zacks Investment Research cut shares of Endologix from a “buy” rating to a “hold” rating in a research note on Thursday, September 12th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $12.88.

Endologix stock traded up $0.10 during midday trading on Wednesday, hitting $3.82. The company’s stock had a trading volume of 87,729 shares, compared to its average volume of 230,143. Endologix has a 1-year low of $3.22 and a 1-year high of $16.00. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.53 and a quick ratio of 1.80. The company has a 50-day moving average price of $4.16 and a two-hundred day moving average price of $6.06. The company has a market cap of $63.93 million, a price-to-earnings ratio of -0.53 and a beta of 0.34.

Several large investors have recently modified their holdings of the company. Walleye Trading Advisors LLC acquired a new position in shares of Endologix in the 2nd quarter valued at approximately $158,000. Walleye Trading LLC acquired a new position in shares of Endologix in the 2nd quarter valued at approximately $158,000. Zacks Investment Management acquired a new position in shares of Endologix in the 2nd quarter valued at approximately $108,000. Jane Street Group LLC acquired a new position in shares of Endologix in the 2nd quarter valued at approximately $91,000. Finally, D. E. Shaw & Co. Inc. raised its position in shares of Endologix by 6.9% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 177,931 shares of the medical instruments supplier’s stock valued at $1,288,000 after buying an additional 11,497 shares in the last quarter. Institutional investors own 77.91% of the company’s stock.

About Endologix

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.

Featured Article: Accumulation/Distribution

Get a free copy of the Zacks research report on Endologix (ELGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.